Real-world observations on neuroinflammation-related drug responses in Alzheimer's disease.
paper
Primary
Public
- Authors
- Xu, Jing; Sun, Anna; Yang, Yuedi; Shi, Yi; Lai, Dongbing; Su, Jing; Li, Lang; Zeng, Donglin; Saykin, Andrew J; Cheng, Feixiong; Liu, Yunlong; Zhang, Pengyue
- Year
- 2025
- Journal
- Journal of Alzheimer's disease : JAD
- PMID
- 40938773
- DOI
- 10.1177/13872877251376291
- PMCID
- PMC12435914
BackgroundAlcohol use disorder (AUD), epilepsy, hemorrhagic stroke (HS), and traumatic brain injury (TBI) are all linked to neuroinflammation and associated with an increased risk of Alzheimer's disease (AD). Drug responses in cognitive health remain largely unknown in patients with neuroinflammation-related conditions.ObjectiveTo investigate the associations between drug exposure and AD incidence in patients with neuroinflammation-related conditions.MethodsWe derived covariate matched cohorts for individuals with and without neuroinflammation-related conditions (e.g., AUD, epilepsy, HS and TBI) from a US nationwide insurance claim data. We used covariate-adjusted Cox models to estimate the hazard ratios (HRs) of drug exposure on AD. We identified neuroinflammation-specific drug responses by comparing HRs between individuals with and without neuroinflammation-related conditions.ResultsWe identified 0.4 million matched pairs of individuals with and without neuroinflammation-related conditions. We identified three drugs (levothyroxine [HR = 0.89], mirabegron [HR = 0.69], and ropinirole [HR = 0.81]) had a lower HR and two drugs (levetiracetam [HR = 1.19], and quetiapine [HR = 1.83]) had a higher HR in individuals with neuroinflammation-related conditions compared to without (false discovery rate <0.05).ConclusionsIn patients with neuroinflammation-related conditions, we identified drugs associated with lower risks (levothyroxine, mirabegron and ropinirole) and higher risks (levetiracetam and quetiapine) of AD incidence.
Illustration of study design and analytical model; A. derivation of analytical datasets; B. Illustration of analytical model.
Associations between tested drugs and Alzheimer’s disease in individuals with and without neuroinflammation-related conditions.
Associations with Alzheimer’s disease; A. Levothyroxine; B. Mirabegron; C. Ropinirole; D. Levetiracetam; E. Quetiapine.
← Prev
21–23 of 23
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| AlAnaziFH, Al-KuraishyHM, AlexiouA, Primary Hypothyroidism and Alzheimer’s Disease: A Tale of Two. Cell Mol Neurobiol 2023; 43: 3405–3416.37540395 10.1007/s10571-023-01392-yPMC10477255 | — | — | — |
| BaileyKC, BurmasterSA, SchaffertJ, Associations of Race-Ethnicity and History of Traumatic Brain Injury With Age at Onset of Alzheimer’s Disease. J Neuropsychiatry Clin Neurosci 2020; 32: 280–285.31619118 10.1176/appi.neuropsych.19010002PMC7162699 | — | — | — |
| BavarsadK, SaadatS, Mohammadian RoshanN, Effects of levothyroxine on lung inflammation, oxidative stress and pathology in a rat model of Alzheimer’s disease. Respir Physiol Neurobiol 2020; 277: 103437.32259689 10.1016/j.resp.2020.103437 | — | — | — |
| BenjaminiY and HochbergY. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 1995; 75: 289–300. | — | — | — |
| BootsmaHP, AldenkampAP, DiepmanL, The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice. Epilepsia 2006; 47 Suppl 2: 24–27.17105455 10.1111/j.1528-1167.2006.00683.x | — | — | — |
| Centers for Disease Control and Prevention (CDC). Alcohol-Related ICD Codes, https://www.cdc.gov/alcohol/ardi/alcohol-related-icd-codes.html (2021, accessed 07/31 2021). | — | — | — |
| ChakkittukandiyilA, ChakrabortyS, KothandanR, Side effects based network construction and drug repositioning of ropinirole as a potential molecule for Alzheimer’s disease: an in-silico, in-vitro, and in-vivo study. J Biomol Struct Dyn 2024; 42: 10785–10799.37723871 10.1080/07391102.2023.2258968 | — | — | — |
| DesaiRJ, VarmaVR, GerhardT, Targeting abnormal metabolism in Alzheimer’s disease: The Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study. Alzheimers Dement (N Y) 2020; 6: e12095.33304987 10.1002/trc2.12095PMC7690721 | — | — | — |
| Echeverry-AlzateV, BuhlerKM, Calleja-CondeJ, Adult-onset hypothyroidism increases ethanol consumption. Psychopharmacology (Berl) 2019; 236: 1187–1197.30470859 10.1007/s00213-018-5123-1 | — | — | — |
| El HusseiniN, KatzanIL, RostNS, Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke 2023; 54: e272–e291.37125534 10.1161/STR.0000000000000430PMC12723706 | — | — | — |
| GallagherJ, GochanourC, Caspell-GarciaC, Long-Term Dementia Risk in Parkinson Disease. Neurology 2024; 103: e209699.39110916 10.1212/WNL.0000000000209699PMC11318527 | — | — | — |
| GaspariniA R Package ‘comorbidity’, https://cran.r-project.org/web/packages/comorbidity/comorbidity.pdf (2022, accessed 03/07 2022). | — | — | — |
| GrieblingTL, CampbellNL, MangelJ, Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr 2020; 20: 109.32183741 10.1186/s12877-020-1474-7PMC7079371 | — | — | — |
| GuD, OuS and LiuG. Traumatic Brain Injury and Risk of Dementia and Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology 2022; 56: 4–16.34818648 10.1159/000520966 | — | — | — |
| HenekaMT, CarsonMJ, El KhouryJ, Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14: 388–405.25792098 10.1016/S1474-4422(15)70016-5PMC5909703 | — | — | — |
| JosephsonCB, EngbersJDT, JetteN, Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription. JAMA Neurol 2019; 76: 440–446.30688969 10.1001/jamaneurol.2018.4561PMC6459128 | — | — | — |
| KamalH, TanGC, IbrahimSF, Alcohol Use Disorder, Neurodegeneration, Alzheimer’s and Parkinson’s Disease: Interplay Between Oxidative Stress, Neuroimmune Response and Excitotoxicity. Front Cell Neurosci 2020; 14: 282.33061892 10.3389/fncel.2020.00282PMC7488355 | — | — | — |
| LambaN, LiuC, ZaidiH, A prognostic role for Low tri-iodothyronine syndrome in acute stroke patients: A systematic review and meta-analysis. Clin Neurol Neurosurg 2018; 169: 55–63.29627642 10.1016/j.clineuro.2018.03.025 | — | — | — |
| LertxundiU, Domingo-EchaburuS, HernandezR, Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics 2013; 13: 17–24.23551407 10.1111/j.1479-8301.2012.00418.x | — | — | — |
| LiKY, LinBT, HsuST, Quetiapine Oral Solution in Alzheimer’s Disease: Efficacy and Dosage Insights from a Real-World Retrospective Study. J Alzheimers Dis 2024; 97: 805–811.38143365 10.3233/JAD-231007 | — | — | — |
| MarchioriRC, PereiraLA, NaujorksAA, Improvement of blood inflammatory marker levels in patients with hypothyroidism under levothyroxine treatment. BMC Endocr Disord 2015; 15: 32.26100072 10.1186/s12902-015-0032-3PMC4476077 | — | — | — |
| MeleC, PaganoL, FranciottaD, Thyroid function in the subacute phase of traumatic brain injury: a potential predictor of post-traumatic neurological and functional outcomes. J Endocrinol Invest 2022; 45: 379–389.34351610 10.1007/s40618-021-01656-8PMC8783844 | — | — | — |
| MielkeMM, RansomJE, MandrekarJ, Traumatic Brain Injury and Risk of Alzheimer’s Disease and Related Dementias in the Population. J Alzheimers Dis 2022; 88: 1049–1059.35723103 10.3233/JAD-220159PMC9378485 | — | — | — |
| MonsourM and BorlonganC. Emerging regenerative medicine for hemorrhagic stroke: An update on stem cell therapies. Brain Hemorrhages 2023; 4. | — | — | — |
| MracskoE and VeltkampR. Neuroinflammation after intracerebral hemorrhage. Front Cell Neurosci 2014; 8: 388.25477782 10.3389/fncel.2014.00388PMC4238323 | — | — | — |
| NasserS, El-AbharHS, El-MaraghyN, Neuroprotective role of mirabegron: Targeting beta-3 adrenergic receptors to alleviate ulcerative colitis-associated cognitive impairment. Biomed Pharmacother 2025; 183: 117816.39809125 10.1016/j.biopha.2025.117816 | — | — | — |
| Neha, AnwarS, Pinky, Ropinirole reverses the effects of neuroinflammation, and cellular demise by downregulating the MARK4-NFkappabeta signaling system in Alzheimer’s disease. Int J Biol Macromol 2024; 271: 132425.38759860 10.1016/j.ijbiomac.2024.132425 | — | — | — |
| NelsonSJ, ZengK, KilbourneJ, Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc 2011; 18: 441–448.21515544 10.1136/amiajnl-2011-000116PMC3128404 | — | — | — |
| NordstromA and NordstromP. Traumatic brain injury and the risk of dementia diagnosis: A nationwide cohort study. PLoS Med 2018; 15: e1002496.29381704 10.1371/journal.pmed.1002496PMC5790223 | — | — | — |
| OrsoM, CozzolinoF, AmiciS, Validity of cerebrovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project. PLoS One 2020; 15: e0227653.31918434 10.1371/journal.pone.0227653PMC6952250 | — | — | — |
| PaleacuD, BarakY, MireckyI, Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer’s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry 2008; 23: 393–400.17879256 10.1002/gps.1892 | — | — | — |
| PoonawallaIB, XuY, GaddyR, Anticholinergic exposure and its association with dementia/Alzheimer’s disease and mortality in older adults. BMC Geriatr 2023; 23: 401.37391728 10.1186/s12877-023-04095-7PMC10311860 | — | — | — |
| SchnierC, DuncanS, WilkinsonT, A nationwide, retrospective, data-linkage, cohort study of epilepsy and incident dementia. Neurology 2020; 95: e1686–e1693.32680951 10.1212/WNL.0000000000010358 | — | — | — |
| St Germaine-SmithC, MetcalfeA, PringsheimT, Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology 2012; 79: 1049–1055.22914826 10.1212/WNL.0b013e3182684707PMC3430709 | — | — | — |
| SulimaiN and LominadzeD. Fibrinogen and Neuroinflammation During Traumatic Brain Injury. Mol Neurobiol 2020; 57: 4692–4703.32776201 10.1007/s12035-020-02012-2PMC7530020 | — | — | — |
| VaisermanA, KoliadaA and LushchakO. Neuroinflammation in pathogenesis of Alzheimer’s disease: Phytochemicals as potential therapeutics. Mech Ageing Dev 2020; 189: 111259.32450086 10.1016/j.mad.2020.111259 | — | — | — |
| VezzaniA, BalossoS and RavizzaT. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol 2019; 15: 459–472.31263255 10.1038/s41582-019-0217-x | — | — | — |
| VosselK, RanasingheKG, BeagleAJ, Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial. JAMA Neurol 2021; 78: 1345–1354.34570177 10.1001/jamaneurol.2021.3310PMC8477304 | — | — | — |
| WilkinsonT, LyA, SchnierC, Identifying dementia cases with routinely collected health data: A systematic review. Alzheimers Dement 2018; 14: 1038–1051.29621480 10.1016/j.jalz.2018.02.016PMC6105076 | — | — | — |
| XuJ, ChenY, ShiY, Associations Between Neuroinflammation-Related Conditions and Alzheimer’s Disease: A Study of US Insurance Claims Data. J Alzheimers Dis 2024; 99: 739–752.38701142 10.3233/JAD-231286PMC11228456 | — | — | — |
| ZhangJ, ZhangY, ZouJ, A meta-analysis of cohort studies: Traumatic brain injury and risk of Alzheimer’s Disease. PLoS One 2021; 16: e0253206.34157045 10.1371/journal.pone.0253206PMC8219123 | — | — | — |
| ZhangP, EdenbergHJ, NurnbergerJ, Alcohol use disorder is associated with higher risks of Alzheimer’s and Parkinson’s diseases: A study of US insurance claims data. Alzheimers Dement (Amst) 2022; 14: e12370.36419637 10.1002/dad2.12370PMC9677510 | — | — | — |
| ZhangP, HouY, TuW, Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer’s disease in African Americans. Alzheimers Dement 2023; 19(5):1876–1887.36331056 10.1002/alz.12819PMC10156891 | — | — | — |
| ZhouB, ZissimopoulosJ, NadeemH, Association between exenatide use and incidence of Alzheimer’s disease. Alzheimers Dement (N Y) 2021; 7: e12139.33614900 10.1002/trc2.12139PMC7882542 | — | — | — |
| ZhouJ, YuJT, WangHF, Association between stroke and Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis 2015; 43: 479–489.25096624 10.3233/JAD-140666 | — | — | — |
No papers in this knowledge base cite this source.
No citations found for this source.